Innovation
in Nucleic Acid Therapeutics for Human Health

OLX101

  • HOME
  • R & D
  • OliX Pipeline
  • OLX101

Scarring

  • is a result of the natural process of wound repair
  • Wound-repair frequently results in scar formation
    in extreme cases - hypertrophic scars or keloids
  • No universal standard of care and no approved drugs for the
    reduction of scarring
  • Scar prevention or reduction is a therapeutic area of
    unmet medical need

비대흉터

Market Potential

  • Global wound and scar therapeutics market is estimated to grow to about $32B (Source : P&S Market Research 2015)

Mechanism

  • Target gene - Connect Tissue Growth Factor (CTGF)

Licensing Out

  • Licensed Out to Huge Inc (2013.11.01) / Territory : Asia
    * Hugel Inc., a Korean drug manufacturer specialized in botulinum toxin and hyaluronic acid filler products (www.hugel.co.kr)

Government Funding

Other Applications of OLX101

└ Applicable to a variety of diseases caused by excessive fibrosis, such as Idiopathic Pulmonary Fibrosis

Publication

  • Hwang, J., Chang, C., Kim, J. H., Oh, C. T., Lee, H. N., Lee, C., Oh, D., Lee, C., Kim, B., Hong, S. W., & Lee, D. K. (2016). Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor. Journal of Investigative Dermatology, 136(11), 2305-2313.